JUBLPHARMA.NS Profit & Loss

Jubilant Pharmova Ltd.

Profit & Loss · 8 years on file (FY2017-18 to FY2025-26) · fetched 2026-08-23 23:33

Line item	FY2017-18	FY2019-20	FY2020-21 standalone basis	FY2021-22	FY2022-23	FY2023-24	FY2024-25	FY2025-26	Source (XBRL element)
Revenue from Operations	₹74.65 Bn	₹91.54 Bn	₹27.09 Bn	₹60.59 Bn	₹62.82 Bn	₹67.03 Bn	₹72.34 Bn	₹82.80 Bn	RevenueFromOperations
Gross Revenue (incl. inter-segment)	₹75.58 Bn	₹91.54 Bn	₹27.09 Bn	₹61.30 Bn	₹62.82 Bn	₹67.03 Bn	₹72.34 Bn	₹82.80 Bn	SegmentRevenueFromOperations
Other Income	₹1.33 Bn	₹0.47 Bn	₹0.48 Bn	₹0.82 Bn	₹0.38 Bn	₹0.69 Bn	₹0.57 Bn	₹0.66 Bn	OtherIncome
Total Income	₹75.98 Bn	₹92.02 Bn	₹27.57 Bn	₹61.41 Bn	₹63.20 Bn	₹67.72 Bn	₹72.91 Bn	₹83.46 Bn	Income
Cost of Materials Consumed	₹26.78 Bn	₹31.19 Bn	₹13.29 Bn	₹13.49 Bn	₹16.66 Bn	₹18.21 Bn	₹19.85 Bn	₹23.20 Bn	CostOfMaterialsConsumed
Purchases of Stock-in-Trade	₹2.43 Bn	₹2.77 Bn	₹0.66 Bn	₹2.02 Bn	₹2.52 Bn	₹2.41 Bn	₹2.97 Bn	₹3.13 Bn	PurchasesOfStockInTrade
Changes in Inventories	₹-0.52 Bn	₹-2.55 Bn	₹0.55 Bn	₹-0.62 Bn	₹-0.41 Bn	₹0.78 Bn	₹0.35 Bn	₹0.11 Bn	ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade
Employee Benefit Expense	₹15.56 Bn	₹21.28 Bn	₹2.21 Bn	₹20.43 Bn	₹21.66 Bn	₹22.16 Bn	₹22.68 Bn	₹27.01 Bn	EmployeeBenefitExpense
Finance Costs	₹2.84 Bn	₹2.87 Bn	₹1.02 Bn	₹1.45 Bn	₹1.88 Bn	₹2.72 Bn	₹2.40 Bn	₹2.12 Bn	FinanceCosts
Depreciation and Amortisation	₹4.15 Bn	₹4.62 Bn	₹1.00 Bn	₹3.82 Bn	₹5.54 Bn	₹3.82 Bn	₹3.69 Bn	₹4.40 Bn	DepreciationDepletionAndAmortisationExpense
Other Expenses	₹16.15 Bn	₹19.39 Bn	₹6.11 Bn	₹14.42 Bn	₹14.62 Bn	₹14.45 Bn	₹14.76 Bn	₹16.75 Bn	OtherExpenses
Total Expenses	₹67.39 Bn	₹79.57 Bn	₹24.84 Bn	₹55.01 Bn	₹62.48 Bn	₹64.56 Bn	₹66.70 Bn	₹76.72 Bn	Expenses
Profit Before Exceptional Items and Tax	₹8.59 Bn	₹12.45 Bn	₹2.73 Bn	₹6.40 Bn	₹0.72 Bn	₹3.15 Bn	₹6.22 Bn	₹6.74 Bn	ProfitBeforeExceptionalItemsAndTax
Exceptional Items	₹0.00 Bn	₹-0.35 Bn	₹0.00 Bn	₹0.00 Bn	₹-0.57 Bn	₹-1.69 Bn	₹3.60 Bn	₹-0.59 Bn	ExceptionalItemsBeforeTax
Profit Before Tax	₹8.59 Bn	₹12.11 Bn	₹2.73 Bn	₹6.40 Bn	₹0.16 Bn	₹1.46 Bn	₹9.81 Bn	₹6.14 Bn	ProfitBeforeTax
Tax Expense	₹2.25 Bn	₹3.12 Bn	₹0.59 Bn	₹2.17 Bn	₹0.93 Bn	₹0.98 Bn	₹1.44 Bn	₹2.17 Bn	TaxExpense
Net Profit (incl. minority interest)	₹6.34 Bn	₹8.98 Bn	₹2.14 Bn	₹4.13 Bn	₹-0.65 Bn	₹0.73 Bn	₹8.36 Bn	₹3.98 Bn	ProfitLossForPeriod
Net Profit (to shareholders)	₹0.00 Bn	₹8.98 Bn	N/A	₹4.14 Bn	₹-0.61 Bn	₹0.77 Bn	₹8.39 Bn	₹3.98 Bn	ProfitOrLossAttributableToOwnersOfParent
Basic EPS	₹41.25	₹56.39	₹13.47	₹26.00	₹-3.83	₹4.87	₹52.99	₹25.15	BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations
Diluted EPS	₹41.25	₹56.39	₹13.47	₹26.00	₹-3.83	₹4.86	₹52.85	₹25.08	DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations

Every figure above is the exact value of the named XBRL element from JUBLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).